ProVac Initiative

Support for national policy choices about new vaccines in low and middle income countries

PI: Andy Clark
Funding: BMGF (via PAHO)

ProVac (promotion of evidence-based decision making for the introduction of new vaccines)started as an initiative in the Americas region of WHO to strengthen national capacity to conduct economic evaluations of new vaccines. An important part of this Initiative has been the development of new decision-support models for use at national level. Researchers from the Vaccine Centre (Andy Clark and Colin Sanderson) have developed an online data repository (www.provac-olives.com) and a suite of user-friendly Excel-based computer models to help national decision-makers evaluate and prioritise vaccines. The TRIVAC model addresses the impact and cost-effectiveness of the new Hib, pneumococcal and rotavirus vaccines for children. The CERVIVAC model evaluates the impact and cost-effectiveness of HPV vaccination for young women, and of improved screening strategies for older women. Typically the process has started with a 2-day international workshop for each vaccine attended by 20+ national teams of Ministry of Health and immunisation programme officials. Sessions are dedicated to sources of relevant data, a demonstration of the model, and trial use of the model by the participants. If a team is interested in going further they embark on a 3-6 month-long country-led process. This involves bringing together national stakeholders, training teams in data collection methods and economic evaluation, and in-country technical support. National Ministry-led teams ultimately present results to national committees. The models have been used by Ministries of Health in Albania, Argentina, Azerbaijan, Belarus, Bolivia, Costa Rica, Croatia, Ecuador, Egypt, El Salvador, Georgia, Guatemala, Honduras, India, Iran, Jamaica, Kenya, Nicaragua, Pakistan, Panama, Paraguay, Peru, Senegal, Uganda, Ukraine, Uruguay and Uzbekistan.

Back